MBMarcel W. Bekkenk

Marcel W. Bekkenk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcel W. Bekkenk has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Revealing Biological Mechanisms of Skin Pigment Recovery during Treatment in Vitiligo Patients; A Proteomic Analysis

    by Emma Holtappels, Nathalie O.P. van Uden, Saskia Chielie, Vidhya S. Narayan, Marcel W. Bekkenk, Albert Wolkerstorfer, Rosalie M. Luiten, Wouter Ouwerkerk

  • Open Access

    Health-related quality of life in patients with basal cell naevus syndrome and high-frequency basal cell carcinoma: a questionnaire study

    by Anna A L Massella Patsea, Myrthe M G Moermans, Babette J A Verkouteren, Patty J Nelemans, Aimée H M M Arits, Marlies Wakkee, Emőke Rácz, Marcel Bekkenk, Klara Mosterd

    Background: Multiple basal cell carcinomas (BCCs) can result from a genetic disease, such as basal cell naevus syndrome (BCNS) or develop without a genetic predisposition, known as high-frequency BCC (HF-BCC). Multiple BCCs require frequent interventions, which may impact quality of life (QoL). Data on QoL in these patients and the influence of number of BCCs on QoL remain scarce. Objectives: To evaluate QoL in patients with BCNS and HF-BCC and the impact of number of BCCs on QoL. Methods: Patients with BCNS were recruited through the Maastricht University Medical Centre (MUMC+), the online national platform for patients with BCNS and through the Dutch Society for Dermatology and Venereology. Patients with HF-BCC (≥ 9 BCCs in 3 years or ≥ 6 in 10 years) were recruited from the MUMC+ and Catharina Hospital Eindhoven. QoL was measured with the Skindex-29 and severity of QoL impact was calculated based on predefined cutoff scores. Results: Seventy-five patients with BCNS and 59 with HF-BCC were included. Patients with BCNS were often younger (median 48 vs. 74 years), 61% (n = 46/75) were women vs. 34% (n = 20/59) of patients with HF-BCC, and 48% (n = 36/75) had > 100 BCCs vs. 2% (n = 1/59) of patients with HF-BCC. A substantial proportion of patients with BCNS reported a severe impact on emotions and functioning [36% (n = 27/75) and 23% (n = 17/75), respectively] and mean (SD) scores of 32.2 (20.8) and 18.9 (19.6), respectively. Adjusting for age and sex, the overall Skindex-29 score was higher in the BCNS group, with a between-group difference of 10 (95% confidence interval 2.5–17.5). Among patients with BCNS, BCC burden was negatively associated with QoL, with significantly higher scores in patients with > 100 compared with < 30 BCCs [mean (SD) total score of 32.0 (19.6) vs. 15.8 (11.6)]. This trend was not observed in patients with HF-BCC. Conclusions: These findings highlight increased QoL impairment in patients with BCNS compared with others with multiple BCCs, especially with respect to emotional and functional wellbeing. This can be partly explained by the high BCC burden in this patient group. Our findings suggest that a high BCC burden is an indicator of psychosocial burden and underscore that disease-related challenges in emotional and social domains should be considered during consultations to improve patient support.


  • Open Access

    Immunity against Non-Melanoma Skin Cancer and the Effect of Immunosuppressive Medication on Non-Melanoma Skin Cancer Risk in Solid Organ Transplant Recipients

    by Dixie Bakker, Walbert J. Bakker, Marcel W. Bekkenk, Rosalie M. Luiten

    Non-melanoma skin cancers (NMSCs) occur frequently in the Caucasian population and are considered a burden for health care. Risk factors include ultraviolet (UV) radiation, ethnicity and immunosuppression. The incidence of NMSC is significantly higher in solid organ transplant recipients (SOTRs) than in immunocompetent individuals, due to immunosuppressive medication use by SOTRs. While the immunosuppressive agents, calcineurin inhibitors and purine analogues increase the incidence of NMSC in transplant recipients, mTOR inhibitors do not. This is most likely due to the different immunological pathways that are inhibited by each class of drug. This review will focus on what is currently known about the immune response against cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), two of the main types of NMSC. Furthermore, we will describe the different classes of immunosuppressants given to SOTRs, which part of the immune system they target and how they can contribute to NMSC development. The risk of developing NMSC in SOTRs is the result of a combination of inhibiting immunological pathways involved in immunosurveillance against NMSC and the direct (pro/anti) tumor effects of immunosuppressants.


  • Open Access

    The Risk of Keratinocyte Cancer in Vitiligo and the Potential Mechanisms Involved

    by Alex Rooker, Wouter Ouwerkerk, Marcel W. Bekkenk, Rosalie M. Luiten, Walbert J. Bakker


  • Open Access

    Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510

    by Selinde S. Wind, Manon A. A. Jansen, Melanie Rijsbergen, Michiel J. van Esdonk, Dimitrios Ziagkos, Wing C. Cheng, Tessa Niemeyer-Van der Kolk, John Korsten, Agnieszka Gruszka, Debora Schmitz-Rohmer, et al.

    The authors wish to make the following corrections to this paper

  • Dermatologic autoimmunity associated with immune checkpoint inhibitors

    by Yannick S. Elshot, Siebe G. Blok, Marcel W. Bekkenk, Tiago R. Matos

  • ESDR503 - Decreased non-melanoma skin cancer prevalence in vitiligo patients: A protective role for the P53 pathway?

    by Alex Rooker, Francisca Vreeswijk, Gabrielle Krebbers, Chuk Wah Wu, Lies Jaspars, Darryl Tio, Marcel Bekkenk, Rosalie Luiten, Walbert Bakker

    Non-melanoma skin cancer (NMSC) represents the most frequent type of cancers among Caucasians. Consisting of basal cell carcinoma (BCC) and squam | POSTER

  • Open Access

    To Refer or Not to Refer in Teledermoscopy: Retrospective Study

    by Esmée Tensen, Femke van Sinderen, Marcel W Bekkenk, Monique W Jaspers, Linda W Peute

    Background: Challenges remain for general practitioners (GPs) in diagnosing (pre)malignant and benign skin lesions. Teledermoscopy (TDsc) supports GPs in diagnosing these skin lesions guided by teledermatologists' (TDs) diagnosis and advice and prevents unnecessary referrals to dermatology care. However, the impact of the availability of TDsc on GPs’ self-reported referral decisions to dermatology care before and after the TDsc consultation is unknown. Objective: The objective of this study is to assess and compare the initial self-reported referral decisions of GPs before TDsc versus their final self-reported referral decisions after TDsc for skin lesions diagnosed by the TD as (pre)malignant or benign. Methods: TDsc consultations requested by GPs in daily practice between July 2015 and June 2020 with a TD assessment and diagnosis were extracted from a nationwide Dutch telemedicine database. Based on GP self-administered questions, the GPs’ referral decisions before and their final referral decision after TDsc consultation were assessed for (pre)malignant and benign TD diagnoses. Results: GP self-administered questions and TD diagnoses were evaluated for 6364 TDsc consultations (9.3% malignant, 8.8% premalignant, and 81.9% benign skin lesions). In half of the TDsc consultations, GPs adjusted their initial referral decision after TD advice and TD diagnosis. Initially, GPs did not have the intention to refer 67 (56.8%) of 118 patients with a malignant TD diagnosis and 26 (16.0%) of 162 patients with a premalignant TD diagnosis but then decided to refer these patients after the TDsc consultation. Furthermore, GPs adjusted their decision from referral to nonreferral for 2534 (74.9%) benign skin lesions (including 676 seborrheic keratosis and 131 vascular lesions). Conclusions: GPs adjusted their referral decision in 52% (n=3306) of the TDsc consultations after the TD assessment. The availability of TDsc is thus of added value and assists GPs in their (non)referral for patients with skin lesions to dermatology care. TDsc resulted in referrals of patients with (pre)malignant skin lesions that GPs would not have referred directly to the dermatologist. TDsc also led to a reduction of unnecessary referrals of patients with low complex benign skin lesions (eg, seborrheic keratosis and vascular lesions).


  • ESDR534 - NB-UVB therapy response of different body regions in vitiligo

    by Vidhya Narayan, Elnaz Alagha, Wouter Ouwerkerk, Sanne Uitentuis, Janny Lommerts, Rania Mogawer, Samia Esmat, Sai Yee Chuah, Steven Thng, Albert Wolkerstorfer, et al.

    Narrow-Band Ultraviolet B (NB-UVB) in combination with topical therapy is a widely used treatment for non-segmental vitiligo (NSV). The location | POSTER

  • ESDR485 - Germline genetic association on efficacy of Immune-checkpoint inhibition in Metastatic Melanoma patients

    by Wouter Ouwerkerk, Saskia Chielie, Marcel Bekkenk, Remco Van Doorn, Christiaan Blank, John Haanen, Geke Hospers, Tomas Kirchhoff, Rosalie M. Luiten, Valeria Teodosieva

    Only ~50% of melanoma patients shows objective response to immune checkpoint inhibitor (ICI) therapy. Currently, there are no reliable predictive | POSTER